Antimutagenic effect of epigallocatechin gallate and its effect on the immune response in mice

Czech Journal of Food Sciences

Volumn 24, Issue 4, 2006, Pages 180-192

  Šmerák, Petr ^a   Šestáková, Helena ^b   Polívková, Zdeňka ^a   Štětina, Rudolf ^c   Langová, Martina ^a   Bárta, Ivo ^a   Turek, Bohumil ^b   Bártová, Jiřina ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Ames test; Antimutagenic effects; Chemiluminescence and blastic transformation tests; Comet assay; Effect on the immune response; Epigallocatechin gallate; Micronucleus test

Indexed keywords

EID: 33747202166     PISSN: 12121800     EISSN: None     Source Type: Journal    
DOI: 10.17221/3315-cjfs     Document Type: Article

References (59)

1. ALVAEEZ E., LEIRO J., ORALLO F. (2002): Effect of (-)-epigallocatechin-3- gallate on respiratory burst of rat macrophages. International Immunopharmacology, 2: 849-855.
2. AMAROWICZ R., PEGG R.B., BAUTISTA D.A. (2000): Antibacterial activity of green tea polyphenols against Escherichia coli K12. Nahrung, 44: 60-62.
3. American Cancer Society (2003): Cancer Facts and Figures 2003. American Cancer Society, Inc.
4. AMES B.N., Mc CANN H.O., YAMASAKI E. (1975): Methods for detecting carcinogens and mutagens with Salmonella/mammalian-microsome mutagenicity test. Mutation Research, 31: 347-364.
5. BANERJEE S., MANNA S., SAHA P., PANDA C.K., DAS S. (2005): Black tea polyphenols suppress cell proliferation and induce apoptosis during benzo(a)pyrene-induced lung carcinogenesis. European Journal of Cancer Prevention, 14: 215-221.
6. BODE A.M., DONG Y. (2004): Targeting signal transduction pathways by chemopreventive agents. Mutation Research, 555: 33-51.
7. BORSKA S., GEBAROWSKA E., WYSOCKA T., DRAG-ZALESINSKA M., ZABEL M. (2003): Induction of apoptosis by EGCG in selected tumour cell lines in vitro. Folia Histochemica et Cytobiologica, 41: 229-232.
8. BUB A., WATZL B., BLOCKHAUS M., BRIVIBA K., LIEGIBEL U., MULLER H., POOL-ZOBEL B.L., RECHKEMMER G. (2003): Fruit juice consumption modulates antioxidative status, immune status and DNA damage. Journal of Nutrition and Biochemistry, 14: 90-98.
9. BUTTERMEYER R., PHILIPP A.W., SCHLENZKA L., MALL J.W., BEISSENHIRTZ M., LISDAT F. (2003): Epigallocatechin gallate can significantly decrease free oxygen radicals in the reperfusion injury in vivo. Transplantation Proceedings, 35: 3116-3120.
10. CHEN L., YANG X., ZHAO B. (2002): Tea catechins protect against lead-induced cytotoxicity, lipid peroxidation, and membrane fluidity in HepG2 cells. Toxicological Sciences, 69: 149-156.
11. CHEN L., YANG X., JIAO H., ZHAO B. (2003): Tea catechins protect against lead-induced ROS formation, mitochondrial dysfunction, and calcium dysregulation in PC12 cells. Chemical Research in Toxicology, 16: 1155-1161.
12. COLLINS A.R., DUŠINSKÁ M., GEDIK C., ŠTĚTINA R. (1996): Oxidative damage to DNA: Do we have a reliable biomarker? Environmental Health Perspectives, 104: 465-469.
13. COLLINS A.R., DOBSON V.L., DUŠINSKÁ M., KENNEDY G., ŠTĚTINA R. (1997): The comet assay: what can really tell us? Mutation Research, 375: 183-194.
14. ČERNÁ M., DOBIÁŠ L., HÁJEK V. (1989): Amesova metoda. V. Metody biologického monitorování genotoxických účinků faktorů prostředí - Standardní metodika. Acta Hygienica, Epidemiologica et Microbiologica, 20 (Příloha): 33-56.
15. DIDIANO D., SHALABY T., LANG D., GROTZER M.A. (2004): Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncology, 6: 1-8.
16. DONA M., DELL' AICA I., CALABRESE F., BENELLI R., MORINI M., ALBINI A., GARBISA S. (2003): Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. Journal of Immunology, 170: 4335-4341.
17. FIELD C.J. (1996): Using immunological techniques to determine the effect of nutrition on T-cell function. Canadian Journal of Pharmacology, 74: 769-777.
18. FUJIKI H., SUGANUMA M., IMAI K., NAKACHI K. (2002): Green tea: cancer preventive beverage and/or drug. Cancer Letters, 188 (1-2): 9-13.
19. GERHAUSER C., KLIMO K., HEISS E., NEUMANN I., GAMAL-ELDEEN A., KNAUFT J., LIU G.Y., SITTHIMONCHAI S., FRANK N. (2003): Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutation Research, 523-524: 163-172.
20. GUPTA S., SAHA B., GIRI A.K. (2002): Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review. Mutation Research, 512: 37-65.
21. GUPTA S., HUSSAIN T., MUKHTAR H. (2003): Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Archives of Biochemistry and Biophysics, 410: 177-185.
22. GUPTA S., HASTAK K., AFAQ F., AHMAD N., MUKHTAR H. (2004): Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor κB and induction of apoptosis. Oncogene, 23: 2507-2522.
23. HENNING S.M., NIU Y., LEE N.H., THAMES G.D., MINUTTI R.R., WANG H., Go V.L., HEBER D. (2004): Bioavailability and antioxidant activity of tea flavonoids after consumption of green tea, black tea, or a green tea extract supplement. American Journal of Clinical Nutrition, 80: 1558-1564.
24. HOUR T.C., LIANG Y.C., CHU I.S., LIN J.K. (1999): Inhibition of 11 mutagens by various tea extracts, (-)-epigallocatechin-3-gallate, gallic acid and caffeine. Food and Chemical Toxicology, 37: 569-579.
25. ITO Y., ITO M. (2001): Suppressive effect of (-)-epigallocatechin gallate on aflatoxin b1-induced chromosome aberrations in rat bone marrow cells. Journal of Health Science, 47: 248-257.
26. KLEBANOFF S.J. (1980): Oxygen metabolism and the toxic properties of phagocytes. Annals of Internal Medicine, 39: 480-489.
27. LAMBERT J.D., YANG C.S. (2003): Mechanisms of cancer prevention by tea constituents. Journal of Nutrition, 133: 3262S-3267S.
28. LEE S.R., IM K.J., SUH S.I., JUNG J.G. (2003): Protective effect of green tea polyphenol (-)-epigallocatechin gallate and other antioxidants on lipid peroxidation in gerbil brain homogenates. Phytotherapeutical Research, 17: 206-209.
29. LEE Y.K., BONE N.D., STREGE A.K., SHANAFELT T.D., JELINEK D.F., KAY N.E. (2004): VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B cell chronic lymphocytic leukemia. Blood, 104: 788-794.
30. LOCHER R., EMMANUELE L., SUTER P.M., VETTER W., BARTON M. (2002): Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein. European Journal of Pharmacology, 434: 1-7.
31. LU H., MENG X., LI C., SANG S., PATTEN C., SHENG S., HONG J., BAI N., WINNIK B., HO C.T., YANG C.S. (2003): Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metabolism and Disposition, 31: 452-461.
32. MARON D.M., AMES B.N. (1983): Revised methods for the Salmonella mutagenicity test. Mutation Research, 113: 173-215.
33. MASUDA M., SUZUI M., LIM J.T., WEINSTEIN I.B. (2003): Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clinical Cancer Research, 9: 3486-3491.
34. MITTAL A., PATE M.S., WYLIE R.C., TOLLEFSBOL T.O., KATIYAR S.K. (2004): EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. International Journal of Oncology, 24: 703-710.
35. MUTO S., FUJITA K., YAMAZAKI Y., KAMATAKI T. (2001): Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutation Research, 497: 197-206.
36. NAKACHI K., MATSUYAMA S., MIYAKE S., SUGANUMA M., IMAI K. (2000): Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors, 13: 49-54.
37. NIHAL M., AHMAD N., MUKHTAR H., WOOD G.S. (2005): Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. International Journal of Cancer, 114: 513-521.
38. PARK O.J., SURH Y.J. (2004): Chemoprotective potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicology Letters, 150: 43-56.
39. REDDY R.V., SHARMA R.P. (1989): Effect of aflatoxin B1 on murine lymphocytic functions. Toxicology, 54: 31-44.
40. ROY M., CHAKRABARTY S., SINHA D., BHATTACHARYA R.K., SIDDIQI M. (2003): Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutation Research, 523-524: 33-41.
41. SAFFARI Y., SADRZADEH S.M. (2004): Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sciences, 74: 1513-1518.
42. SAH J.F., BALASUBRAMANIAN S., ECKERT R.L., RORKE E.A. (2004): Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and Akt kinases. Journal of Biological Chemistry, 279: 12755-12762.
43. SARCAR F.H., LI Y. (2004): Cell signaling pathways altered by natural chemopreventive agents. Review Mutation Research, 555: 53-64.
44. SARTOR L., PEZZATO E., DONA M., DELL'AICA I., CALABRESE F., MORINI M., ALBINI A., GARBISA S. (2004): Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. International Journal of Cancer, 112: 823-829.
45. SCHMID W. (1975): The Micronucleus test. Mutation Research, 31: 9-15.
46. SINGH N.P., COY M.T., TICE R.R., SCHNEIDER E.L. (1988): A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research, 175: 184-191.
47. SKRZYDLEWSKA E., OSTROWSKA J., FARBISZEWSKI R., MICHALAK K. (2002): Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and brain. Phytomedicine, 9: 232-238.
48. STITES D.P., TERR A. (1994): Základní a klinická imunologie. Victoria Publ. a.s., Praha.
49. STRATIL P., KUBÁŇ V. (2004): Princip karcinogeneze a přírodní karcinogenní sloučeniny v potravinách. Chemické Listy, 98: 379-387.
50. SUGISAWA A., KIMURA M., FENECH M., UMEGAKI K. (2004): Anti-genotoxic effects of tea catechins against reactive oxygen species in human lymphoblastoid cells. Mutation Research, 559: 97-103.
51. ŠESTÁKOVÁ H., TUREK B., ŠMERÁK P., SEDMÍKOVÁ M. (1997): Sledováni chemiluminiscenč ní reakce u myší po ovlivnění rostlinnými látkami a vitaminy. Potravinářské Vědy, 15: 437-450.
52. ŠMERÁK P., POLÍVKOVÁ Z., ŠESTÁ KOVÁ H., ŠTĚTINA R., BÁRTA I., LANGOVÁ M., TUREK B., BÁRTOVÁ J. (2006): Antimutagenic effect of curcumin and its effect on the immune response in mice. Czech Journal of Food Sciences, 24: 72-83.
53. TOMAR R.S., LIM S., GILL S.S. (1991): The effect of epoxidized xenobiotics on mitogen responsivenes and antibody producing ability of murine spleen cells in vitro. International Journal of Immunopharmacology, 13: 57-65.
54. YAMAMOTO Y., MATSUNAGA K., FRIEDMAN H. (2004a): Protective effect of green tea catechins on alveolar macrophages against bacterial infections. Biofactors, 21: 119-121.
55. YAMAMOTO T., LEWIS J., WATAHA J., DICKINSON D., SINGH B., BOLLAG W.B., UETA E., OSAKI T., ATHAR M., SCHUSTER G., HSU S. (2004b): Roles of catalase and hydrogen peroxide in green tea polyphenol-induced. Journal of Pharmacology and Experimental Therapeutics, 308: 317-323.
56. YOKOYAMA M., NOGUCHI M., NAKAO Y., PATER A., IWASAKA T. (2004): The tea polyphenol, (-)-epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecologic Oncology, 92: 197-204.
57. WANG Y.C., BACHRACH U. (2002): The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids, 22: 131-143.
58. WEISBURGER J.H., HARA Y., DOLAN L., LUO F.-Q., PITTMAN B., ZANG E. (1996): Tea polyphenols as inhibitors of mutagenicity of major classes of carcinogens. Mutation Research, 371: 57-63.
59. ZHU M., GONG Y., YANG Z., GE G., HAN C., CHEN J. (1999): Green tea and its major components ameliorate immune dysfunction in mice bearing Lewis lung carcinoma and treated with the carcinogen NNK. Nutrition and Cancer, 35: 64-72.